Shots: BioNTech unveils the plan to develop the first mRNA-based vaccine to prevent malaria with anticipated initiation of the clinical study by the end of 2022 The company intends to […]readmore
Tags : Initiate
Shots: The P-II trial will evaluate the efficacy, safety, and tolerability of KN046 + Pfizer’s Inlyta (axitinib) as a 1L treatment of NSCLC. The 1EPs of the study are ORR […]readmore
Shots: The P-I study will evaluate the PK and safety profile of R-107 vs PBO in patients with PAH. Earlier, Claritas licensed R-107 from Salzman Group and collaborated with it, […]readmore
Shots: The company plan to initiate a pivotal P-IIIa program to assess the efficacy and safety of oral semaglutide (50mg) vs PBO in ~1000 people with obesity or overweight with […]readmore
Shots: The P-III LELANTOS-2 study will assess Pamrevlumab + systemic corticosteroids vs PBO + systemic corticosteroids in ~70 patients aged 6-12yrs. in a ratio (1:1) with ambulatory DMD for up […]readmore
Shots: The companies reported the initiation of P-I/II trial to evaluate the safety, tolerability, and immunogenicity of MRT5500 (1 or 2doses given 21 days apart) vs PBO in ~415 healthy […]readmore
Shots: The NMPA has approved Lee pharma to initiate P-III clinical trials to evaluate Socazolimab + CT as a 1L treatment of ES-SCLC. The study is expected to initiate patient […]readmore
Shots: The companies reported the initiation of a P-II dose-finding study assessing the safety, reactogenicity, and immunogenicity of two injections given 21 days apart in 720 adults aged ≥18yrs. The […]readmore
Shots: Clover plans to initiate a global P-II/III efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum in the H1’2021 with an interim analysis for […]readmore
Shots: Gristone to receive $60M at closing, including $30M up front and a $30M as an equity investment at a premium and is eligible to receive up to ~$725M as […]readmore